CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - UK
Summary
GlobalData, the industry analysis specialist, has released its latest report, CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - UK. The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in the UK. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of the UK. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.
The value of the UK pharmaceutical market increased from £13.2bn ($20.3bn) in 2010 to £19.6bn ($25.9bn) in 2017, at a compound annual growth rate (CAGR) of 5.9% in the terms of GBP and 3.5% in the terms of US$. The market is expected to reach £26.2bn ($30.9bn) in 2022. The increased usage of personalized medicines, incorporating digital technology into drug development and accelerating drug access pathway, high disease burden and rise in elderly population are the main driving factors of pharmaceutical market. In 2015, the medical device market in the UK was worth $17.8 billion, which increased to $19.1 billion in 2017 at a CAGR of 3.6%. It is expected to grow at a CAGR of 4.1% from $19.8 billion in 2018 to $26.3 billion in 2025. The main segments were in vitro diagnostics, ophthalmic devices, cardiovascular devices, wound care devices and orthopedic devices. The development in personalized or precision medicines, incorporation of genetic sequencing and personal genome data, is revolutionizing the approach medical practitioners and pharmaceutical industries are undertaking for the disease treatment.
Scope
The report provides information on the healthcare, regulatory, and reimbursement landscape in the UK, and includes -
- An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
- Profiles and SWOT analyses of the major players in the pharmaceutical market (AstraZeneca, GlaxoSmithKline, Merck, Novartis and Pfizer) and profiles and SWOT analyses of the major players in the medical device market (Siemens, Roche, DePuy, Essilor and Smith & Nephew)
- Detailed analysis about recent completed deals in the pharmaceutical and medical device market of the UK
- Porter’s five forces analysis for pharmaceutical and medical devices market of the UK
- An insightful review of the reimbursement and regulatory landscape.
of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices- Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
- An overview of the opportunities for and challenges to growth in the UK healthcare market.
Reasons to buy
This report will enhance your decision-making capability by allowing you to - - Develop business strategies by understanding the trends shaping and driving the UK healthcare market
- Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
- Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
- Identify, understand, and capitalize on the opportunities and challenges in the UK healthcare market.
- Executive Summary
- Overview of Pharmaceutical Market
- Overview of Medical Device Market
- Deals Analysis
- Porter’s Five Forces Model
- Market Access
- Country Healthcare Landscape
- Opportunities and Challenges
- Appendix
- List of Tables
- Table 1: Pharmaceutical Market, UK, Sales of Patented Drug Products by Major Therapeutic Class ($bn), 2016 26
- Table 2: Medical Device Market, UK, Revenue by Segment ($bn), 2017 46
- Table 3: InVitro Diagnostics Devices Market, UK, Revenue and Market Share of Major Players 47
- Table 4: Ophthalmic Devices Market, UK, Revenue and Market Share of Major Players 48
- Table 5: Cardiovascular Devices Market, UK, Revenue and Market Share of Major Players 49
- Table 6: Wound Care Devices Market, UK, Revenue and Market Share of Major Players 50
- Table 7: Orthopedic Devices Market, UK, Revenue and Market Share of Major Players 51
- Table 8: Market Access, Forecasts and Profile Of Annual Payment Percentages, UK, 2014-2018 94
- Table 9: Patent Fees ($), 2018, UK 116
- Table 10: Trademark Fees ($), 2018, UK 119
- Table 11: Clinical Trials Application Fees ($), 2018, UK 122
- Table 12: Clinical Trials Application Fees ($) for Medical Devices, 2018, UK 122
- Table 13: Trade Associations, UK 144
- Table 14: Trade Fairs, UK 145
- List of Figures
- Figure 1: Pharmaceutical Market, UK, Revenue, 2015-2022 8
- Figure 2: Medical Device Market, UK, Revenue, 2015-2020 8
- Figure 3: UK Brexit Timeline, UK, 2018 12
- Figure 4: Number of Deals (2017-2018) 14
- Figure 5: 2017-2018 Deal Overview By Region 14
- Figure 6: Country Profile, UK, 2018 16
- Figure 7: Pharmaceutical Market, UK, Revenue, 2010-2017 18
- Figure 8: Pharmaceutical Market, UK, Revenue Forecast, 2018-2022 18
- Figure 9: Pharmaceutical Market, UK, Pharmaceutical Exports 19
- Figure 10: Pharmaceutical Market, UK, Top Export Partners 19
- Figure 11: Pharmaceutical Market, UK, Pharmaceutical Imports 20
- Figure 12: Pharmaceutical Market, UK, Top Import Partners 20
- Figure 13: Pharmaceutical Market, UK, Supply Channels 21
- Figure 14: Pharmaceutical Market, UK, Sales of OTC drugs by Major Therapeutic Segments, 2018 25
- Figure 15: Pharmaceutical Market, UK, Sales of Patented Drug Products by Major Therapeutic Class, 2016 26
- Figure 16: Pharmaceutical Market, UK, Sales of Patented Drug Products by Major Therapeutic Class ($bn), 2016 26
- Figure 17: Pharmaceutical Market, UK, Major Players 28
- Figure 18: Medical Device Market, UK, Revenue, 2015-2020 45
- Figure 19: Medical Device Market, UK, Revenue Forecast, 2021-2025 45
- Figure 20: Medical Device Market, UK, Revenue by Segment, 2017 46
- Figure 21: InVitro Diagnostics Devices Market, UK, Revenue 47
- Figure 22: InVitro Diagnostics Devices Market, UK, Market Share of Major Players 47
- Figure 23: Ophthalmic Devices Market, UK, Revenue 48
- Figure 24: Ophthalmic Devices Market, UK, Market Share of Major Players 48
- Figure 25: Cardiovascular Devices Market, UK, Revenue 49
- Figure 26: Cardiovascular Devices Market, UK, Market Share of Major Players 49
- Figure 27: Wound Care Devices Market, UK, Revenue 50
- Figure 28: Wound Care Devices Market, UK, Market Share of Major Players 50
- Figure 29: Orthopedic Devices Market, UK, Revenue 51
- Figure 30: Orthopedic Devices Market, UK, Market Share of Major Players 51
- Figure 31: Diagnostic Market, UK, Revenue ($bn), 2015-2020 52
- Figure 32: Diagnostic Market, UK, Revenue Forecast ($bn), 2021-2025 52
- Figure 33: Medical Device Market, UK, Revenue of Major Players, 2016 54
- Figure 34: Deal Value and Deal Count, Pharmaceutical Market, UK, 2017-2018 74
- Figure 35: Deal Value and Deal Count Quarterly, Pharmaceutical Market, UK, 2017-2018 74
- Figure 36: Deal Value and Deal Count Sub-types, Pharmaceutical Market, UK, 2017-2018 74
- Figure 37: Top Five Therapy Area by Deal Value, Pharmaceutical Market, UK, 2017-2018 75
- Figure 38: Top Five Therapy Area by Deal Number, Pharmaceutical Market, UK, 2017-2018 75
- Figure 39: M&A Deals by Therapy Area, Pharmaceutical Market, UK, 2017-2018 75
- Figure 40: Venture Financing Deals by Therapy Area, Pharmaceutical Market, UK, 2017-2018 75
- Figure 41: Private Equity Deals by Therapy Area, Pharmaceutical Market, UK, 2017-2018 75
- Figure 42: Medical Device Market Deals, UK, 2017-2018 (by Deal Value, $m) 76
- Figure 43: Medical Device Market Deals, UK, 2017- 2018 (by Deal Count) 76
- Figure 44: Medical Device Market Deals Share (by Deal Count), UK, 2017-2018 76
- Figure 45: Medical Device Market Deals Share (by Deal Value), UK, 2017-2018 76
- Figure 46: Medical Device, Top Therapy Area by Deal Value, UK, 2017-2018 77
- Figure 47: Medical Device, Top Therapy Area by Deal Number, UK, 2017-2018 77
- Figure 48: M&A Deals by Therapy Area, Medical Device, UK, 2017-2018 (by Value and by Number) 77
- Figure 49: Venture Financing Deals by Therapy Area, Medical Device, UK, 2017-2018 (by Value and by Number) 77
- Figure 50: Private Equity Deals by Therapy Area, Medical Device, UK, 2017-2018 (by Value and by Number) 77
- Figure 51: Healthcare Market, UK, Overview of Health System, 2018 82
- Figure 52: Overview of Finance Flow, UK, 2018 83
- Figure 53: NHS Departmental Expenditure Limit ($bn), UK, 2015-2021 84
- Figure 54: Market Access, Reimbursement Schemes, UK, 2016 88
- Figure 55: OOP Expenditure (% of Total Expenditure on Health), UK, 2010-2017 91
- Figure 56: Annual Average Rates of Price Change (%), Medicines Price Index, UK, 2010-2017 91
- Figure 57: Market Access, MHRA Structure, UK, 2018 96
- Figure 58: Centralized Procedure, UK, 2018 101
- Figure 59: Centralized Procedure, EU, 2018 102
- Figure 60: Decentralized Procedure, EU, 2018 103
- Figure 61: Mutual Recognition Procedure, UK, 2018 104
- Figure 62: Life Cycle of Medical Device, UK, 2018 105
- Figure 63: Conformity Assessment of Class I Medical Devices, EU, 2018 109
- Figure 64: Conformity Assessment of Class IIa Medical Devices, EU, 2018 110
- Figure 65: Conformity Assessment of Class IIb Medical Devices, EU, 2018 111
- Figure 66: Conformity Assessment of Class III Medical Devices, EU, 2018 112
- Figure 67: Licensing Procedure for Pharmaceutical Manufacturing, UK, 2018 113
- Figure 68: Patent Approval Process, UK, 2018 115
- Figure 69: European Patent Approval Process, EU, 2017 117
- Figure 70: Unitary Patent Approval Process, EU, 2017 118
- Figure 71: Trademark Approval Process, UK, 2018 119
- Figure 72: Clinical Trial Authorization (CTA) Application Flowchart, 2017, UK 121
- Figure 73: Market Access, UK, Clinical Trial Regulation Process for Medical Devices, 2018 123
- Figure 74: Market Access, Regulatory Changes in the UK Before and After Brexit, 2018 128
- Figure 75: Number of Hospitals, UK, 2010-2017 136
- Figure 76: Diagnostic Equipment (per Million Population), UK, 2010-2017 136
- Figure 77: Hospital Beds (per 1,000 Population), UK 137
- Figure 78: Psychiatric Hospital Beds (per 1,000 Population), UK 137
- Figure 79: Life Expectancy, 2010-2017, UK 138
- Figure 80: Immunization Rate (%), 2010-2017, UK 138
- Figure 81: PM2.5 (μg per m3), UK, 2010-2017 139
- Figure 82: CO2 Emissions (Million Tons), UK, 2010-2017 139
- Figure 83: Physicians (per 1,000 Population), UK, 2010-2016 140
- Figure 84: Nurses (per 1,000 Population), UK, 2010-2016 140
- Figure 85: Dentists (per 1,000 Population), UK, 2010-2016 140
- Figure 86: Pharmacists (per 1,000 Population), UK, 2010-2016 140
- Figure 87: Major Causes of Mortality (per 1,000 Population), UK, 2016 141
- Figure 88: Major Causes of Male Mortality, UK, 2016 141
- Figure 89: Major Causes of Female Mortality, UK, 2016 141
- Figure 90: Disability-Adjusted Life Years by Major Disease (‘000), UK, 2016 141
- Figure 91: Healthcare Expenditure as Percentage of GDP (%), UK, 2010-2017 142
- Figure 92: Public-Private Share (%), UK, 2010-2017 142
- Figure 93: Major Components of Healthcare Spending (%), UK, 2016 143
- Figure 94: Opportunities and Challenges, UK 147